PURPOSE: To assess the diagnostic value of O-2-fluoro-18(F)-ethyl-L-tyrosine ((18)F-FET) positron emission tomography/computed tomography (PET/CT) for patients with advanced head and neck squamous cell carcinoma compared with 18F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT at initial staging and following radiochemotherapy. PROCEDURES: Thirteen patients were prospectively enrolled; each of them underwent an (18)F-FDG PET/CT and (18)F-FET PET/CT before treatment. Ten of those were scanned 10 weeks after treatment. RESULTS: Sensitivity, specificity, and accuracy for (18)F-FDG PET/CT (primary and lymph node metastases) at initial staging were 89%, 50%, and 81%. For (18)F-FET PET/CT the numbers were 70%, 90%, and 74%. Sensitivity, specificity, and accuracy for (18)F-FDG PET/CT at follow-up were 71%, 65%, and 67%. For (18)F-FET PET/CT the numbers were 29%, 100%, and 83%. Additionally, (18)F-FDG PET/CT detected a higher number of second malignancies or distant metastases. CONCLUSIONS: (18)F-FET is no substitute for (18)F-FDG. Although it is more specific, too many malignant lesions are missed due to its lower sensitivity.
PURPOSE: To assess the diagnostic value of O-2-fluoro-18(F)-ethyl-L-tyrosine ((18)F-FET) positron emission tomography/computed tomography (PET/CT) for patients with advanced head and neck squamous cell carcinoma compared with 18F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT at initial staging and following radiochemotherapy. PROCEDURES: Thirteen patients were prospectively enrolled; each of them underwent an (18)F-FDG PET/CT and (18)F-FET PET/CT before treatment. Ten of those were scanned 10 weeks after treatment. RESULTS: Sensitivity, specificity, and accuracy for (18)F-FDG PET/CT (primary and lymph node metastases) at initial staging were 89%, 50%, and 81%. For (18)F-FET PET/CT the numbers were 70%, 90%, and 74%. Sensitivity, specificity, and accuracy for (18)F-FDG PET/CT at follow-up were 71%, 65%, and 67%. For (18)F-FET PET/CT the numbers were 29%, 100%, and 83%. Additionally, (18)F-FDG PET/CT detected a higher number of second malignancies or distant metastases. CONCLUSIONS: (18)F-FET is no substitute for (18)F-FDG. Although it is more specific, too many malignant lesions are missed due to its lower sensitivity.
Authors: Andrew Quon; Nancy J Fischbein; I Ross McDougall; Quynh-Thu Le; Billy W Loo; Harlan Pinto; Michael J Kaplan Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057
Authors: Jolijn Brouwer; Asaf Senft; Remco de Bree; Emile F I Comans; Richard P Golding; Jonas A Castelijns; Otto S Hoekstra; C René Leemans Journal: Oral Oncol Date: 2005-11-02 Impact factor: 5.337
Authors: Achim H Kaim; Bruno Weber; Michael O Kurrer; Gerrit Westera; Alain Schweitzer; Jochen Gottschalk; Gustav K von Schulthess; Alfred Buck Journal: Eur J Nucl Med Mol Imaging Date: 2002-03-06 Impact factor: 9.236
Authors: S Balogova; S Périé; K Kerrou; D Grahek; F Montravers; B Angelard; B Susini; P El Chater; J Lacau St Guily; J N Talbot Journal: Mol Imaging Biol Date: 2008-07-31 Impact factor: 3.488
Authors: Rosana S Rodrigues; Fernando A Bozza; Paul E Christian; John M Hoffman; Regan I Butterfield; Carl R Christensen; Marta Heilbrun; Richard H Wiggins; Jason P Hunt; Brandon G Bentz; Ying J Hitchcock; Kathryn A Morton Journal: J Nucl Med Date: 2009-07-17 Impact factor: 10.057
Authors: Klaus Strobel; Stephan K Haerle; Sandro J Stoeckli; Madeleine Schrank; Jan D Soyka; Patrick Veit-Haibach; Thomas F Hany Journal: Eur J Nucl Med Mol Imaging Date: 2009-02-10 Impact factor: 9.236
Authors: Johnny Kao; Ha Linh Vu; Eric M Genden; Bharat Mocherla; Eunice E Park; Stuart Packer; Peter M Som; Lale Kostakoglu Journal: Cancer Date: 2009-10-01 Impact factor: 6.860
Authors: Jurjan R de Boer; Bernard F A M van der Laan; Jan Pruim; Tjin H Que; Fred Burlage; Allard Krikke; Antoon T M Willemsen; Anton T M G Tiebosch; Frans W J Albers; Willem Vaalburg Journal: Eur J Nucl Med Mol Imaging Date: 2002-06-15 Impact factor: 9.236
Authors: Jan Wedman; Jan Pruim; Jan L N Roodenburg; Gyorgy B Halmos; Johannes A Langedijk; Rudi A J O Dierckx; Bernard F A M van der Laan Journal: Eur Arch Otorhinolaryngol Date: 2012-12-27 Impact factor: 2.503